Required CCSG Acknowledgement

The NCI requires that publications acknowledge the UPCI CCSG support, and they are tracking compliance. If a UPCI CCSG-supported Shared Resource provided data used in your publication, please include the following statement in the acknowledgment section of your publication(s):

"This project used the UPCI [insert name(s) of shared resource(s)] that [is/are] supported in part by award P30CA047904."

Shared Resource Directors: Please make sure to include this statement on all of your order forms, contracts, etc. as a reminder to your users to acknowledge the UPCI CCSG support.

Clinical Imaging

Advances in cancer management will require the development of new therapies that can be tested in clinical trials, state-of-the-art imaging technologies to assess response to those therapies, and innovative research that can lead to the development of even more powerful imaging technologies in the future.

There is a vital need for quantitative assessment of cancer therapy response. Computed tomography (CT) and standard magnetic resonance imaging (MRI) cannot provide information on the biochemical and physiologic properties of cancer tissues. The UPCI IVIF provides novel quantitative imaging techniques that trace biomarkers of molecular events associated with effective cancer therapy. Early imaging of such fundamental molecular pathways corresponding to effective treatment is now playing an increasingly vital role in patient cancer therapy management. Development and use of quantitative imaging for early therapy assessment will become critical to future management by sparing patients weeks or months of toxic and ineffective treatment.